

Resource Summary Report

Generated by [RRID](#) on Sep 9, 2026

PC3

RRID:CVCL_E2RM

Type: Cell Line

Proper Citation

RRID:CVCL_E2RM

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_E2RM

Proper Citation: RRID:CVCL_E2RM

Description: Cell line PC3 is a Hybridoma with a species of origin Mus musculus (Mouse)

Defining Citation: [PMID:26090594](#)

Category: Hybridoma

Organism: Mus musculus (Mouse)

Name: PC3

ID: CVCL_E2RM

Hierarchy: cvcl_3411

Record Creation Time: 20240911T072004+0000

Record Last Update: 20260905T183432+0000

Ratings and Alerts

No rating or validation information has been found for PC3.

No alerts have been found for PC3.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Monteagudo-García Ó, et al. (2026) ZC3H13 Loss Drives Cancer Metastatic Progression by Disrupting m6A RNA Methylation. *Cancer research*, 86(3), 622.

Huang J, et al. (2026) The FOSB-IGFBP5-IGF-1 axis: a novel regulatory pathway that suppresses prostate cancer growth. *Cancer gene therapy*.

Tang H, et al. (2026) Aryl Aldehyde-Anchored Small Molecules Recruit FBXO22 for Targeted Degradation of NSD2. *Journal of medicinal chemistry*, 69(13), 15317.

Peng Y, et al. (2026) SDP-LIV1, a Novel and Optimized LIV-1 Antibody-Drug Conjugate Demonstrating Superior Antitumor Efficacy and a Favorable Safety Profile for the Treatment of Solid Tumors. *Molecular cancer therapeutics*, 25(2), 322.

Schober AS, et al. (2026) USP29-regulated noncanonical stabilization of the hypoxia-inducible factor-? in aggressive prostate cancer. *Molecular oncology*.

Kim M, et al. (2026) Bone Metastatic Progression of Prostate Cancer Is Regulated by TRIM28-LDHA-Mediated Metabolism. *Molecular cancer research : MCR*, 24(2), 93.

Huang KH, et al. (2026) TG-interacting factor 1 mediates TNF-induced Ccl2 expression in adipocytes to promote prostate cancer progression. *FEBS letters*, 600(13), 1885.

Liu SS, et al. (2026) Epigenetic regulation of NDGA and its synergistic inhibition with EZH2 inhibitors in prostate cancer via NRP1. *Acta pharmacologica Sinica*, 47(6), 1643.

Brandariz J, et al. (2025) Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer. *Molecular cancer therapeutics*, 24(12), 1959.

Johnson CS, et al. (2025) Targeted Deletion of Cxcl1 in MSCs Regulates Osteogenesis and Suppresses Bone-Metastatic Prostate Cancer. *Molecular cancer research : MCR*, 23(8), 739.

Porazzi P, et al. (2025) EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models. *Cancer cell*, 43(3), 537.